Targeted Tumor Therapy Based on Nanodiamonds Decorated with Doxorubicin and Folic Acid | Zendy

Ryu TaeKyung | Zendy; Baek Seung Woon | Zendy; Lee GyoungJa | Zendy; Rhee ChangKyu | Zendy; Choi SungWook | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Targeted Tumor Therapy Based on Nanodiamonds Decorated with Doxorubicin and Folic Acid

Author(s) -

Ryu TaeKyung,

Baek Seung Woon,

Lee GyoungJa,

Rhee ChangKyu,

Choi SungWook

Publication year - 2017

Publication title -

macromolecular bioscience

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.924

H-Index - 105

eISSN - 1616-5195

pISSN - 1616-5187

DOI - 10.1002/mabi.201600180

Subject(s) - folate receptor , doxorubicin , carbodiimide , nanodiamond , chemistry , drug delivery , conjugated system , targeted drug delivery , in vivo , folic acid , drug , cancer research , pharmacology , biophysics , chemotherapy , biochemistry , cancer cell , cancer , medicine , biology , surgery , organic chemistry , microbiology and biotechnology , diamond , polymer

The fabrication of nanodiamond (ND)‐based drug carriers for tumor‐targeted drug delivery is described. The ND clusters with an average size of 52.84 nm are fabricated using a simple fluidic device combined with a precipitation method and then conjugated with folic acid (FA) and doxorubicin (Dox) via carbodiimide chemistry to obtain FA/Dox‐modified ND (FA/Dox‐ND) clusters. Cell culture experiments revealed that KB (folate receptor‐positive) cells are preferentially ablated by FA/Dox‐ND clusters compared to A549 (folate receptor‐negative) cells. In vivo results revealed that FA/Dox‐ND clusters are specifically accumulated in tumor tissues after intravenous injection into tumor‐bearing mice, effectively reducing the volume of tumor. Based on these results, this study suggests that FA/Dox‐ND clusters can be a good candidate as tumor‐targeted nanovehicles for delivery of antitumor drug.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research